However, the vast majority of NSCLC patients have acquired resistance to EGFR-TKIs, in which the EGFRT790M mutation accounts for approximately 50% of all 1st-generation TKIs resistant cases13. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.